Tuesday, Illumina Inc. (ILMN), a maker of tools for analysis of genes and biological function, posted a profit in the third quarter, reflecting improved revenues and the absence of a year-ago charge. However, the company lowered its outlook for fiscal 2009. Following the announcement, the stock lost nearly 17% in the after hours.
The San Diego, California-based Illumina posted net income of $17.1 million or $0.12 per share for the third quarter, compared to a net loss of $10.1 million or $0.08 per share a year ago.
Illumina said its recent quarter included non-cash charges of $14.6 million in stock compensation expense, $4.8 million in non-cash interest expense, and other items, while last year's included a $24.7 million in process research and development charge associated with its acquisition of Avantome, Inc.
Excluding items, Illumina's adjusted net income was $32.3 million or $0.24 per share, up from $28.64 million or $0.22 per share for the third quarter of 2008. On average, thirteen analysts polled by Thomson Reuters expected the company to earn $0.20 per share for the quarter. Analysts' estimates typically exclude special items.
Quarterly revenues increased 5% to $158.36 million from $150.26 million reported in the third quarter of 2008. Analysts projected revenues of $167.32 million.
In the preceding second quarter, Illumina reported net income of $24.7 million or $0.18 per share, up from $12.7 million or $0.09 per share a year ago. Adjusted net income increased to $39.4 million or $0.30 per share from $27.5 million or $0.22 per share in the same quarter of last year. Revenues grew 15% to $161.6 million from last year's $140.2 million.
For the quarter under review, product revenues rose to $150.31 million from $140.32 million a year ago, while service and other revenues dipped to $8.05 million from $9.94 million in the prior year period.
Gross margin in the latest quarter was 67.6%, compared to 62.0% a year ago. Excluding the effect of non-cash charges associated with stock compensation and the amortization of intangibles, non-GAAP gross margin was 69.5% for the quarter, compared to 64.6% in the prior year period.
Research and development expenses increased to $34.4 million from $27.6 million in the prior year period.
The company generated $23.1 million in cash flow from operations during the quarter, compared to $27.3 million in the prior year period.
Year-to-date, Illumina's net income surged to $60.58 million or $0.44 per share from $13.32 million or $0.10 per share in the corresponding period. Adjusted net income was $107.11 million or $0.82 per share, compared to $78.57 million or $0.63 per share in the previous year. For the nine-month period, the company generated revenues of $485.76 million, up from $412.3 million a year ago.
For the fourth quarter of 2009, the company expects non-GAAP earnings of $0.24 to $0.25 per share and minimum revenues of $165 million. The Street expects earnings of $0.27 per share, on revenue of $200.16 million for the quarter.
Lowering its outlook for the full-year 2009, the company said it now expects non-GAAP earnings of $1.05 - $1.06 per share, and revenues of $651 million. Analysts project earnings of $0.89 per share, on revenue of $694.82 million, for the year.Earlier, the company had estimated non-GAAP earnings of $1.13 to $1.23 per share and revenues of $690 million - $720 million.
Among the peers, biotechnology tools company Life Technologies Corp. (LIFE) reported a surge in profit for the third quarter, above analysts' estimates, reflecting strong growth in Europe, Asia Pacific, Japan and the majority of product areas. The company also raised its full-year adjusted earnings per share guidance.
Life Technologies' third-quarter net income totaled $41.14 million or $0.22 per share, higher than $18.78 million or $0.19 per share in the same quarter last year. Excluding items, net income increased significantly to $134.64 million or $0.73 per share from $61.46 million or $0.63 per share last year. The Carlsbad, California-based company's quarterly revenues surged to $800.73 million from $361.70 million in the prior-year quarter.
ILMN closed Tuesday's trading at $41.66, up $0.64 or 1.56%, on a volume of about 5.29 million shares. In the after hours, the stock lost $6.08 or 14.59% and traded at $35.50.
For the past 52-week period, the stock traded in the range of $18.82 - $44.07, on a 3-month average volume of about 1.46 million shares.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.